⌘K
Loading ticker…
As of 2026-08-21, Neurocrine Biosciences Inc (NBIX) has a 3-month relative strength percentile of 43 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.3%, relative volume 0.84×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
NBIX is held by 57 ETFs as of May 2026. Top owner: VHT at 0.25% weight, $47M notional. Top 3 carry $124M.
Held by 191 ETFs · $3.0B across latest filings · largest weight 4.66% (PSIL).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.25% | $47M | +0.06 pp |
| SCHMSchwab U.S. Mid-Cap ETF | 0.29% | $43M | +0.03 pp |
| SCHGSchwab U.S. Large-Cap Growth ETF | 0.05% | $34M | — |
| IVOO | 0.45% | $25M | +0.07 pp |
| VONGVanguard Russell 1000 Growth ETF | 0.04% | $22M | — |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $17M | — |
| IVOG | 0.87% | $16M | +0.14 pp |
| FNDA | 0.16% | $14M | +0.04 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.02% | $9M | — |
| QQQJ | 0.74% | $8M | +0.09 pp |
Showing 10 of 57 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NBIX Jan avg: 1.53% median: 1.00% win: 50% σ: 8.58% n: 4 2022-04-12 → 2026-07-31 | NBIX Feb avg: -9.59% median: -6.88% win: 0% σ: 8.37% n: 4 2022-04-12 → 2026-07-31 | NBIX Mar avg: -0.82% median: -1.10% win: 25% σ: 5.19% n: 4 2022-04-12 → 2026-07-31 | NBIX Apr avg: -2.34% median: -0.28% win: 0% σ: 3.64% n: 5 2022-04-12 → 2026-07-31 | NBIX May avg: 5.07% median: 3.84% win: 60% σ: 12.55% n: 5 2022-04-12 → 2026-07-31 | NBIX Jun avg: 3.98% median: 4.27% win: 100% σ: 2.04% n: 5 2022-04-12 → 2026-07-31 | NBIX Jul avg: 1.69% median: 2.02% win: 60% σ: 4.35% n: 5 2022-04-12 → 2026-07-31 | NBIX Aug avg: 4.16% median: 7.87% win: 75% σ: 9.77% n: 4 2022-04-12 → 2026-07-31 (current) | NBIX Sep avg: -0.98% median: 1.03% win: 75% σ: 5.67% n: 4 2022-04-12 → 2026-07-31 | NBIX Oct avg: 3.35% median: 3.20% win: 75% σ: 4.11% n: 4 2022-04-12 → 2026-07-31 | NBIX Nov avg: 6.78% median: 5.82% win: 100% σ: 2.45% n: 4 2022-04-12 → 2026-07-31 | NBIX Dec avg: 1.98% median: 0.85% win: 50% σ: 9.91% n: 4 2022-04-12 → 2026-07-31 |